189 related articles for article (PubMed ID: 21679142)
1. Novel therapies for Pseudomonas aeruginosa pneumonia.
Roux D; Ricard JD
Infect Disord Drug Targets; 2011 Aug; 11(4):389-94. PubMed ID: 21679142
[TBL] [Abstract][Full Text] [Related]
2. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study.
Bouglé A; Foucrier A; Dupont H; Montravers P; Ouattara A; Kalfon P; Squara P; Simon T; Amour J;
Trials; 2017 Jan; 18(1):37. PubMed ID: 28114979
[TBL] [Abstract][Full Text] [Related]
3. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
[TBL] [Abstract][Full Text] [Related]
4. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
[TBL] [Abstract][Full Text] [Related]
5. The rapid
Wang K; Chen YQ; Salido MM; Kohli GS; Kong JL; Liang HJ; Yao ZT; Xie YT; Wu HY; Cai SQ; Drautz-Moses DI; Darling AE; Schuster SC; Yang L; Ding Y
Open Biol; 2017 Sep; 7(9):. PubMed ID: 28878043
[No Abstract] [Full Text] [Related]
6. Relative contribution of three main virulence factors in Pseudomonas aeruginosa pneumonia.
Le Berre R; Nguyen S; Nowak E; Kipnis E; Pierre M; Quenee L; Ader F; Lancel S; Courcol R; Guery BP; Faure K;
Crit Care Med; 2011 Sep; 39(9):2113-20. PubMed ID: 21572326
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
[TBL] [Abstract][Full Text] [Related]
8. Update on the treatment of Pseudomonas aeruginosa pneumonia.
El Solh AA; Alhajhusain A
J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections.
Maurice NM; Bedi B; Sadikot RT
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):428-439. PubMed ID: 29372812
[TBL] [Abstract][Full Text] [Related]
10. Rapid genetic and phenotypic changes in Pseudomonas aeruginosa clinical strains during ventilator-associated pneumonia.
Persyn E; Sassi M; Aubry M; Broly M; Delanou S; Asehnoune K; Caroff N; Crémet L
Sci Rep; 2019 Mar; 9(1):4720. PubMed ID: 30886315
[TBL] [Abstract][Full Text] [Related]
11. New therapies for pneumonia.
Ricard JD
Curr Opin Pulm Med; 2012 May; 18(3):181-6. PubMed ID: 22388584
[TBL] [Abstract][Full Text] [Related]
12. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
[TBL] [Abstract][Full Text] [Related]
13. [Pneumonia due to Pseudomonas aeruginosa].
Vallés J; Mariscal D
Enferm Infecc Microbiol Clin; 2005 Dec; 23 Suppl 3():30-6. PubMed ID: 16854339
[TBL] [Abstract][Full Text] [Related]
14. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
Arnold HM; Sawyer AM; Kollef MH
Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial.
van Delden C; Köhler T; Brunner-Ferber F; François B; Carlet J; Pechère JC
Intensive Care Med; 2012 Jul; 38(7):1118-25. PubMed ID: 22527075
[TBL] [Abstract][Full Text] [Related]
16. Rational approach in the management of Pseudomonas aeruginosa infections.
Bassetti M; Vena A; Russo A; Croxatto A; Calandra T; Guery B
Curr Opin Infect Dis; 2018 Dec; 31(6):578-586. PubMed ID: 30299364
[TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Bassetti M; Castaldo N; Cattelan A; Mussini C; Righi E; Tascini C; Menichetti F; Mastroianni CM; Tumbarello M; Grossi P; Artioli S; Carannante N; Cipriani L; Coletto D; Russo A; Digaetano M; Losito AR; Peghin M; Capone A; Nicolè S; Vena A;
Int J Antimicrob Agents; 2019 Apr; 53(4):408-415. PubMed ID: 30415002
[TBL] [Abstract][Full Text] [Related]
18. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.
Hamer DH
Am J Respir Crit Care Med; 2000 Jul; 162(1):328-30. PubMed ID: 10903263
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia.
Chen C; Deslouches B; Montelaro RC; Di YP
Clin Microbiol Infect; 2018 May; 24(5):547.e1-547.e8. PubMed ID: 28882728
[TBL] [Abstract][Full Text] [Related]
20. Baicalin inhibits biofilm formation, attenuates the quorum sensing-controlled virulence and enhances Pseudomonas aeruginosa clearance in a mouse peritoneal implant infection model.
Luo J; Dong B; Wang K; Cai S; Liu T; Cheng X; Lei D; Chen Y; Li Y; Kong J; Chen Y
PLoS One; 2017; 12(4):e0176883. PubMed ID: 28453568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
